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A reliable assessment of glomerular filtration rate (GFR) is of paramount importance in clinical practice as well as
epidemiological and clinical research settings. It is recommended by Kidney Disease: Improving Global Outcomes guidelines in
specific populations (anorectic, cirrhotic, obese, renal and non-renal transplant patients) where estimation equations are
unreliable. Measured GFR is the only valuable test to confirm or confute the status of chronic kidney disease (CKD), to evaluate
the slope of renal function decay over time, to assess the suitability of living kidney donors and for dosing of potentially toxic
medicationwith a narrow therapeutic index. Abnormally elevatedGFRor hyperfiltration in patientswith diabetes or obesity can
be correctly diagnosed only by measuring GFR. GFR measurement contributes to assessing the true CKD prevalence rate,
avoiding discrepancies due toGFRestimationwith different equations. UsingmeasuredGFR, successfully accomplished in large
epidemiological studies, is the onlyway to study the potential link betweendecreased renal function and cardiovascular or total
mortality, being sure that this association is not due to confounders, i.e. non-GFR determinants of biomarkers. In clinical
research, it has been shown that measured GFR (or measured GFR slope) as a secondary endpoint as compared with estimated
GFR detected subtle treatment effects and obtained these results with a comparatively smaller sample size than trials choosing
estimated GFR. Measuring GFR by iohexol has several advantages: simplicity, low cost, stability and low interlaboratory
variation. Iohexol plasma clearance represents the best chance for implementing a standardized GFR measurement protocol
applicable worldwide both in clinical practice and in research.
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Introduction
The first part of this review article focused on practical and tech-
nical aspects of iohexol plasma clearance [i.e. plasma iohexol
analysis and clearance investigation procedures (number of sam-
ples and timing)]. In this second part, we focus on the indication
of glomerular filtration rate (GFR) measurements in clinical prac-
tice as wellas in epidemiological and clinical research.
Role of iohexol in clinical practice
It is beyond the scope of this article to review and summarize all
clinical settings where measured GFR is recommended [1–3].
Briefly, and as stated in the Kidney Disease: Improving Global
Outcomes guidelines [4], additional tests for GFR assessment
are needed in specific populations where creatinine-based equa-
tions are unreliable, because serum creatinine is largely depend-
ent on muscle mass [5]. Cystatin C can be used as an alternative
test but is influenced by other non-GFR-related factors such as
obesity, thyroid function and cardiovascular risk factors [6–11].
Thus,measuredGFR is recommended for specific patients or sub-
jects with an abnormalmusculemass or body composition, such
as anorectic, cirrhotic, obese and renal and non-renal transplant
patients [2, 12–17]. If, in daily practice, repeatedmeasurements of
GFR in these patient groups are infeasible, at least one GFRmeas-
urement will indicate the relationship between serum creatinine
(or plasma cystatin C) concentrations and the ‘true’ GFR level.
Measured GFR is the only available test to certify GFR levels,
and according to the GFR level, to confirm or refute chronic kid-
ney disease (CKD) status. Also, in longitudinal studies, several
authors have described the limitations of estimated GFR (eGFR)
to adequately assess the true decline in measured GFR [17–21].
Another clear indication for GFR measurement applies when
an exact value of GFR is required [4]. The two typical examples are
the measurement of GFR before potential living kidney donation
or before prescribing a potentially toxic hydrosoluble drug with a
narrow therapeutic window, e.g. aminoglycosides or cisplatin [1,
22–24]. Finally, without measured GFR, one pathological condi-
tion in nephrology would remain undetected. Abnormally ele-
vated GFR, or hyperfiltration, has been established as an initial
pathophysiological step to CKD in patients with diabetes and
may also be of importance in common conditions such as
obesity,metabolic syndrome and prediabetes [25, 26]. Important-
ly, data suggest that treating hyperfiltration with angiotensin-
converting enzyme inhibitors could be beneficial [27, 28]. How-
ever, it is well accepted that the condition of hyperfiltration can
only be correctly detected with measured GFR, as all eGFR equa-
tions perform poorly in this specific, highly relevant pathological
state [16, 17, 22].
Role of iohexol in clinical research
The role of measured GFR in both clinical epidemiology and clin-
ical research is another important objective of this review.
Clinical epidemiology
Measuring GFR is also feasible in large epidemiological studies.
For example, the CRIC (Chronic Renal Insufficiency Cohort), BIS
(Berlin Initiative Study), AGES-II (Age, Gene/Environment Sus-
ceptibility) and RENIS (Renal Iohexol Clearance Survey) studies
are four large observational cohorts with GFRmeasured by iotha-
lamate (CRIC) and iohexol (BIS, AGES-II and RENIS) [29–33]. The
RENIS study is interesting since it is a European observational
study with a representative sample of the general population in
Tromsø, Norway, and GFR measurement has been repeated in
the follow-up [26, 31]. The BIS study also measured GFR with io-
hexol plasma clearance in a large population-based cohort of
older patients (mean age 79 years), which also proves the feasibil-
ity of performing measured GFR in this fragile age group [32, 34].
Data from numerous epidemiological studies show high but
different prevalence rates of CKD in the general population.
Moreover, CKD status is associatedwithmortality, especially car-
diovascular mortality [8, 35–38]. However, the vast majority of
these epidemiological studies are based on eGFR. It is known
that all eGFR equations, based on creatinine and/or cystatin C,
have limitations, particularly at high GFR levels [2, 39, 40]. Also,
it has been shown that the prevalence of CKD is largely depend-
ent on the equation [Modification of Diet in Renal Disease (MDRD)
versus Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) versus Cockcroft–Gault] and biomarker used (creatin-
ine versus cystatin C) [37, 41]. The major limitations of GFR esti-
mations include issues in calibration of the biomarkers [42],
different performance of the estimators according to age [43]


















and lack of precision in high GFR values [2]. Even if data are lim-
ited, we cannot exclude that the prevalence of CKD in the general
population, defined as GFR <60 mL/min/1.73 m2, may be much
lower with measured GFR compared with eGFR [31].
The higher risk of mortality associated with decreased GFR is
another hot topic in clinical epidemiology [4, 36, 44]. Once again,
associations between cardiovascular risk and CKD have been de-
scribed with eGFR in the vastmajority of patients. This fact could
lead to confusion or false-positive associations, as eGFR may in-
clude variables such as gender, ethnicity, weight and age that are
per se risk factors for cardiovascular morbidity and mortality and
often referred to as ‘non-GFR determinant’. The differentweights
of these factors in different equations might explain differences
in the magnitude of association between cardiovascular out-
comes and eGFR [45, 46]. Some authors have suggested a closer
association between mortality and the Cockcroft–Gault equation
comparedwith theMDRD study equation [45]. The fact that age is
handled differently mathematically in the two equations could
explain the discrepancies. The association between eGFR and
mortality also varies with the biomarker considered. For cystatin
C–versus creatinine-based equations, an increased hazard ratio
for all-cause mortality was found for eGFR <85 mL/min/1.73 m2
based on cystatin C, but when the eGFR was based on creatinine,
the hazard ratio increased when eGFR was <60 mL/min/1.73 m2
[47, 48].
Also, the classical association between theMDRD (or CKD-EPI)
equation and mortality is U-shaped, with a higher mortality at
high GFR values. This U-shaped association has not been found
when cystatin C–based equations were investigated [36, 44, 49].
Overall, it is virtually impossible to knowwhether this U-shaped
association is (i) a mathematical artefact, (ii) due to hyperfiltra-
tion (true elevated GFR) or (iii) due to sarcopenia and falsely low
creatinine concentrations. Measured GFR has recently been dis-
credited because it was insufficiently able to predict mortality
compared with creatinine- or cystatin C–based equations [50].
Using measured GFR is, however, the only way to really study
the potential link between decreased renal function and cardio-
vascular or total mortality, being sure that this association is not
due to confounders, i.e. non-GFR determinants of biomarkers
[muscule mass (serum creatinine), traditional cardiovascular
risk factors (cystatin C) and non-traditional cardiovascular risk
factors (creatinine and cystatin C)] [6, 7, 9, 51–53].
Clinical research
In nephrological trials, the classic clinical endpoints are mortal-
ity, end-stage renal disease or doubling of serum creatinine.
However, these are relatively rare events developing over a long
period of time, especially in low-risk patients. For this reason,
clinical studies in nephrology require large sample sizes and a
long follow-up time. Therefore, several authors proposed so-
called surrogate markers instead of ‘true’ endpoints. GFR and
albuminuria are the two most reliable surrogate markers to use
[54]. However, eGFR lacks precision, especially at high GFR levels,
and is, as mentioned above, not only dependent on GFR, but also
on non-GFR determinants included in the equations. Moreover,
several authors have described large discrepancies between
slopes based onmeasured GFR versus eGFR [17–21]. Themajority
of these studies have shown that the decline in measured GFR is
underestimated by eGFR. For these reasons, detection of poten-
tial differences in GFR slopes between two groups (e.g. one trea-
ted with active therapy and the other with placebo) requires
larger sample sizes with eGFR than with measured GFR. An ex-
ample is the trial of belatacept in renal transplant patients,
which showed a benefit of belatacept therapy when measured
GFRwasused,whereas a non-significant differencewas observed
with eGFR [55]. Importantly, the number of patients with mea-
sured GFR in the three groups was relatively small (n = 32 in the
intensive belatacept group, n = 37 in the less intensive group
and n = 27 in the cyclosporine group). Another illustrative ex-
ample is the ALADIN (A Long-Acting Somatostatin on Disease
Progression in Nephropathy due to Autosomal Dominant Poly-
cystic Kidney Disease) trial in which the efficacy of somatostatin
in polycystic kidney disease was studied. The slope of measured
GFR was an important secondary endpoint. The authors were
able to show that the slope ofmeasuredGFRwas significantly dif-
ferent between treatment groups (n = 36 and 34 in the active and
placebo arm, respectively) [56]. Such important results would have
been missed if only eGFR had been used [21]. A similar trial with
similar results was published using tolvaptan. The authors also
showed a significantly different slope in eGFR after 3 years of fol-
low-up between the tolvaptan and placebo groups, but had to in-
clude 1445 patients to detect this significant difference [57].
The lack of precision of eGFR is also particularly important in
the context of drug dosage adaptation. It is beyond the scope of
this article to discuss all the limitations of equations in this con-
text [58]. Due to these limitations, the European Medicines
Agency now recommends that ‘a method accurately measuring
GFR using an exogenousmarker [should be] used in pharmacoki-
netic studies in subjects with decreased renal function’ [59].
Conclusions
In conclusion, both in clinical practice and in research, measured
GFR is considered too rarely. Nephrology is certainly the only dis-
cipline where a gold standard measurement is so uncommonly
used. Measuring GFR by iohexol has several advantages: simpli-
city, low cost, stability and low interlaboratory variation. We are
convinced that iohexol plasma clearance is the best chance to
implement a standardized GFR measurement protocol that
would be applicableworldwide both in clinical practice and in re-
search. Even if it is not as perfect as the ‘gold standard’ method
(inulin urinary clearance), iohexol plasma clearance appears to
provide the best compromise between physiology, reliability
and feasibility.
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